Lucerastat
Product Specifications
UNSPSC Description
Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].
Target Antigen
Glucosylceramide Synthase (GCS)
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/lucerastat.html
Solubility
DMSO : 22 mg/mL (ultrasonic;warming;heat to 80°C)|H2O : 24 mg/mL (ultrasonic;warming;heat to 80°C)
Smiles
O[C@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O
Molecular Weight
219.28
References & Citations
[1]Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.|[2]R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-106392/Lucerastat-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-106392/Lucerastat-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
141206-42-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
